LC
CBIO

Lindbrook Capital’s Crescent Biopharma CBIO Stock Holding History

Lindbrook Capital’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20
Closed -$1K – 2730
2022
Q2 		$1K Buy
+20
New +$1.48K ﹤0.01% 2245
2021
Q4 		– Sell
-50
Closed -$11K – 2127
2021
Q3 		$11K Buy
+50
New +$10.6K ﹤0.01% 956

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Lindbrook Capital's CBIO Position: Q3 2022 in Review

Lindbrook Capital sold out of Crescent Biopharma (CBIO) in Q3 2022, closing a stake of 20 shares — an estimated $1K sold.

Lindbrook Capital first reported a position in CBIO in Q3 2021 and held it in 2 quarters. The position peaked at $11K in Q3 2021. 34 funds tracked by Wall St. Rank hold CBIO as of Q3 2022.

  • Lindbrook Capital reported no remaining Crescent Biopharma position as of Q3 2022 after selling out during the quarter.
  • Lindbrook Capital sold 20 Crescent Biopharma shares in Q3 2022, an estimated $1K.
  • Lindbrook Capital first reported a position in Crescent Biopharma in Q3 2021 and held it in 2 quarters.
  • Lindbrook Capital's Crescent Biopharma position peaked at $11K in Q3 2021.
  • 34 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2022.

Based on Lindbrook Capital's 13F filing for Q3 2022, filed 10 Nov 2022.